Osteopore (ASX:OSX) reported the early cessation of its AU$18.7 million dental grant clinical-industrial partnership project after a strategic review, according to a Thursday Australian bourse filing.
The decision will allow for a reallocation of resources and align with its near- and mid-term objectives of prioritizing commercialization.
The firm had been looking for opportunities to improve cost center performance while at the same time streamlining expenses.
Its shares rose 10% on market close on Thursday.